Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 231.3 Million EUR | -37.47% |
| 2022 | 439.6 Million USD | 64.09% |
| 2021 | 267.9 Million EUR | -22.05% |
| 2020 | 343.69 Million EUR | 22.87% |
| 2019 | 279.72 Million EUR | 12.34% |
| 2018 | 249 Million EUR | -11.1% |
| 2017 | 280.1 Million EUR | -3.75% |
| 2016 | 291 Million EUR | 1.13% |
| 2015 | 287.76 Million EUR | 5.64% |
| 2014 | 272.4 Million EUR | 1.76% |
| 2013 | 267.7 Million EUR | -3.81% |
| 2012 | 278.3 Million EUR | -1.63% |
| 2011 | 282.9 Million EUR | 9.44% |
| 2010 | 258.5 Million EUR | 21.88% |
| 2009 | 212.1 Million EUR | 10.07% |
| 2008 | 192.7 Million EUR | -0.93% |
| 2007 | 194.5 Million EUR | 113.97% |
| 2006 | 90.9 Million EUR | -48.96% |
| 2005 | 178.1 Million EUR | 33.91% |
| 2004 | 133 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 59.56 Million EUR | -3.33% |
| 2024 Q2 | 65.8 Million EUR | 17.21% |
| 2024 Q3 | 202 Million EUR | 212.21% |
| 2023 Q1 | 59.5 Million USD | 41.11% |
| 2023 FY | 274.9 Million EUR | -37.47% |
| 2023 Q4 | 63.02 Million EUR | -25.38% |
| 2023 Q3 | 84.46 Million USD | 87.49% |
| 2023 Q2 | 45.04 Million USD | -24.29% |
| 2022 Q3 | 238.34 Million EUR | 183.57% |
| 2022 FY | 439.6 Million USD | 64.09% |
| 2022 Q2 | 84.04 Million EUR | 18.21% |
| 2022 Q4 | 42.16 Million USD | -82.31% |
| 2022 Q1 | 71.1 Million EUR | 80.0% |
| 2021 Q4 | 39.5 Million EUR | -30.34% |
| 2021 Q1 | 87.32 Million EUR | 155.34% |
| 2021 Q2 | 78.62 Million EUR | -9.96% |
| 2021 Q3 | 56.7 Million EUR | -27.89% |
| 2021 FY | 267.9 Million EUR | -22.05% |
| 2020 Q3 | 65.1 Million EUR | -32.47% |
| 2020 Q1 | 84.4 Million EUR | 53.45% |
| 2020 Q2 | 96.4 Million EUR | 14.22% |
| 2020 FY | 343.69 Million EUR | 22.87% |
| 2020 Q4 | 34.2 Million EUR | -47.47% |
| 2019 Q2 | 52.1 Million EUR | -5.27% |
| 2019 Q1 | 55 Million EUR | -19.83% |
| 2019 FY | 279.72 Million EUR | 12.34% |
| 2019 Q4 | 55 Million EUR | -39.36% |
| 2019 Q3 | 90.7 Million EUR | 74.09% |
| 2018 FY | 249 Million EUR | -11.1% |
| 2018 Q4 | 68.6 Million EUR | 53.81% |
| 2018 Q3 | 44.6 Million EUR | -36.01% |
| 2018 Q2 | 69.7 Million EUR | -0.14% |
| 2018 Q1 | 69.8 Million EUR | -5.29% |
| 2017 Q4 | 73.7 Million EUR | 34.24% |
| 2017 Q3 | 54.9 Million EUR | -22.13% |
| 2017 Q2 | 70.5 Million EUR | -20.07% |
| 2017 Q1 | 88.2 Million EUR | 50.26% |
| 2017 FY | 280.1 Million EUR | -3.75% |
| 2016 Q3 | 92 Million EUR | 10.18% |
| 2016 Q4 | 58.7 Million EUR | -36.2% |
| 2016 Q1 | 80.3 Million EUR | 57.76% |
| 2016 Q2 | 83.5 Million EUR | 3.99% |
| 2016 FY | 291 Million EUR | 1.13% |
| 2015 Q3 | 58.6 Million EUR | -20.81% |
| 2015 FY | 287.76 Million EUR | 5.64% |
| 2015 Q4 | 50.9 Million EUR | -13.14% |
| 2015 Q2 | 74 Million EUR | -10.95% |
| 2015 Q1 | 83.1 Million EUR | 50.54% |
| 2014 Q3 | 63.8 Million EUR | -25.81% |
| 2014 Q1 | 67.4 Million EUR | 2.28% |
| 2014 Q4 | 55.2 Million EUR | -13.48% |
| 2014 FY | 272.4 Million EUR | 1.76% |
| 2014 Q2 | 86 Million EUR | 27.6% |
| 2013 Q1 | 74.1 Million EUR | 33.51% |
| 2013 FY | 267.7 Million EUR | -3.81% |
| 2013 Q2 | 61.1 Million EUR | -17.54% |
| 2013 Q4 | 65.9 Million EUR | -1.05% |
| 2013 Q3 | 66.6 Million EUR | 9.0% |
| 2012 FY | 278.3 Million EUR | -1.63% |
| 2012 Q1 | 78.6 Million EUR | 27.8% |
| 2012 Q4 | 55.5 Million EUR | -26.59% |
| 2012 Q3 | 75.6 Million EUR | 15.77% |
| 2012 Q2 | 65.3 Million EUR | -16.92% |
| 2011 Q1 | 94.2 Million EUR | 76.07% |
| 2011 Q3 | 66 Million EUR | -0.6% |
| 2011 Q4 | 61.5 Million EUR | -6.82% |
| 2011 FY | 282.9 Million EUR | 9.44% |
| 2011 Q2 | 66.4 Million EUR | -29.51% |
| 2010 Q3 | 71.3 Million EUR | 15.75% |
| 2010 Q4 | 53.5 Million EUR | -24.96% |
| 2010 Q1 | 72 Million EUR | 61.07% |
| 2010 FY | 258.5 Million EUR | 21.88% |
| 2010 Q2 | 61.6 Million EUR | -14.44% |
| 2009 Q2 | 51.4 Million EUR | -12.88% |
| 2009 FY | 212.1 Million EUR | 10.07% |
| 2009 Q4 | 44.7 Million EUR | -21.3% |
| 2009 Q3 | 56.8 Million EUR | 10.51% |
| 2009 Q1 | 59 Million EUR | 0.0% |
| 2008 FY | 192.7 Million EUR | -0.93% |
| 2007 FY | 194.5 Million EUR | 113.97% |
| 2006 FY | 90.9 Million EUR | -48.96% |
| 2005 FY | 178.1 Million EUR | 33.91% |
| 2004 FY | 133 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | 97.177% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 98.659% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | 96.703% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 682.15% |
| Novartis AG | 9.76 Billion USD | 97.632% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 99.994% |